financetom
Business
financetom
/
Business
/
IsoEnergy 2024 Winter Exploration Program Confirms Anomalies, Identifies New Targets
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
IsoEnergy 2024 Winter Exploration Program Confirms Anomalies, Identifies New Targets
Apr 25, 2024 5:51 AM

08:28 AM EDT, 04/25/2024 (MT Newswires) -- IsoEnergy ( ISENF ) said on Thursday that winter 2024 exploration work on its uranium properties in the eastern Athabasca Basin confirmed anomalies and identified new targets that will be tested during its summer exploration program that begins in June.

The winter program included 7,227 meters of drilling in 13 diamond drill holes on the Larocque East and Hawk projects, the company said. At Larocque East, the campaign defined a large hydrothermal system typically associated with unconformity uranium deposits in the Athabasca basin. Results at Hawk elevated the potential the project has a large uranium deposit.

"We are strongly encouraged by the results from our first drill testing of the [ambient noise tomography or ANT] anomalies identified at the Laroque East and Hawk projects," CEO Phil Williams said. "In both cases, drilling proved that the ANT surveys correctly show alteration, a prerequisite for mineralization, and will serve as an important targeting tool going forward."

IsoEnergy's ( ISENF ) shares dropped 1.3% yesterday to $3.72.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Merck Initiates Phase 3 Trial to Evaluate Essential Thrombocythemia Treatment Candidate
Merck Initiates Phase 3 Trial to Evaluate Essential Thrombocythemia Treatment Candidate
Aug 27, 2024
07:18 AM EDT, 08/27/2024 (MT Newswires) -- Merck ( MRK ) said Tuesday it has initiated a phase 3 clinical trial to evaluate bomedemstat, an investigational LSD1 inhibitor, for treating essential thrombocythemia in patients who have not previously received cytoreductive therapy. The trial, which is enrolling around 300 patients, will compare bomedemstat to the standard chemotherapy treatment, hydroxyurea. The primary...
Avicanna Announced U.S. Patent and Trademark Office Issuance of Patent on Topical Technology
Avicanna Announced U.S. Patent and Trademark Office Issuance of Patent on Topical Technology
Aug 27, 2024
07:56 AM EDT, 08/27/2024 (MT Newswires) -- Avicanna Inc. ( AVCNF ) , a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, announced Tuesday the United States Patent and Trademark Office issuance of the Patent covering Avicanna's ( AVCNF ) deep penetrating topical cannabinoid composition and methods for treating musculoskeletal inflammation and pain. We are...
Philip Morris International Invests $232 Million to Expand Kentucky Facility
Philip Morris International Invests $232 Million to Expand Kentucky Facility
Aug 27, 2024
07:58 AM EDT, 08/27/2024 (MT Newswires) -- Philip Morris International ( PM ) said Tuesday it invested $232 million through its Swedish Match affiliate to expand production at its Owensboro, Kentucky, facility, which manufactures ZYN nicotine pouches. The project is expected to create 450 direct jobs and generate a $277 million annual economic impact, with another 410 indirect jobs for...
Clear Blue Technologies Q2 Loss Narrows as Revenue Rises 35%
Clear Blue Technologies Q2 Loss Narrows as Revenue Rises 35%
Aug 27, 2024
07:15 AM EDT, 08/27/2024 (MT Newswires) -- Clear Blue Technologies International ( CBUTF ) overnight Monday said its second-quarter net loss narrowed by a third as revenue rose 35%. The company, which creates and manages power products and services for lower cost off-grid and hybrid energy, said the net loss fell to $1.4 million from $2 million last year. The...
Copyright 2023-2026 - www.financetom.com All Rights Reserved